418 related articles for article (PubMed ID: 10713629)
1. A phase II study of two cycles of high-dose chemotherapy with autologous stem cell support in patients with metastatic breast cancer who meet eligibility criteria for a single cycle.
Bashey A; Corringham S; Garrett J; Lane TA; Gilpin EA; Corringham RE; Law P; Ho AD
Bone Marrow Transplant; 2000 Mar; 25(5):519-24. PubMed ID: 10713629
[TBL] [Abstract][Full Text] [Related]
2. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.
Elias AD; Richardson P; Avigan D; Ibrahim J; Joyce R; Demetri G; Levine J; Warren D; Arthur T; Reich E; Wheele C; Frei E; Ayash L
Bone Marrow Transplant; 2001 Feb; 27(3):269-78. PubMed ID: 11277174
[TBL] [Abstract][Full Text] [Related]
3. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
4. Mobilized peripheral blood progenitor cells (PBPC) in support of tandem cycles of high-dose chemotherapy (HDC).
Meisenberg BR; Miller WE; McMillan R
Bone Marrow Transplant; 1996 Dec; 18(6):1087-93. PubMed ID: 8971377
[TBL] [Abstract][Full Text] [Related]
5. [Combination of high-dose chemotherapy with autologous hematopoietic stem cell transplantation for recurrent and high-risk breast cancer: a pilot study].
Shi Y; Pan F; Han X
Zhonghua Yi Xue Za Zhi; 1999 Dec; 79(12):890-3. PubMed ID: 11715500
[TBL] [Abstract][Full Text] [Related]
6. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation.
Demirer T; Uysal VA; Ayli M; Genc Y; Ilhan O; Koc H; Dagli M; Arat M; Gunel N; Fen T; Dincer S; Ustael N; Yildiz M; Ustun T; Seyrek E; Ozet G; Muftuoglu O; Akan H
Bone Marrow Transplant; 2003 May; 31(9):755-61. PubMed ID: 12732881
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.
Vahdat LT; Balmaceda C; Papadopoulos K; Frederick D; Donovan D; Sharpe E; Kaufman E; Savage D; Tiersten A; Nichols G; Haythe J; Troxel A; Antman K; Hesdorffer CS
Bone Marrow Transplant; 2002 Aug; 30(3):149-55. PubMed ID: 12189532
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer.
Schrama JG; Baars JW; Holtkamp MJ; Schornagel JH; Beijnen JH; Rodenhuis S
Bone Marrow Transplant; 2001 Jul; 28(2):173-80. PubMed ID: 11509935
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer.
Kröger N; Frick M; Gluz O; Mohrmann S; Metzner B; Jackisch C; Ko Y; Lindemann HW; Meier CR; Lohrmann HP; Ruffert U; Hänel M; Bodenstein H; Neubauer A; Ehninger G; Wolf HH; Kolbe K; Burock K; Zander AR; Nitz U
J Clin Oncol; 2006 Aug; 24(24):3919-26. PubMed ID: 16921043
[TBL] [Abstract][Full Text] [Related]
10. High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma - a phase II study.
Toh HC; McAfee SL; Sackstein R; Multani P; Cox BF; Garcia-Carbonero R; Colby C; Spitzer TR
Bone Marrow Transplant; 2000 Jan; 25(1):19-24. PubMed ID: 10654009
[TBL] [Abstract][Full Text] [Related]
11. High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: a 10-year experience.
Laport GF; Grad G; Grinblatt DL; Bitran JD; Williams SF
Bone Marrow Transplant; 1998 Jan; 21(2):127-32. PubMed ID: 9489628
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
Hanrahan EO; Broglio K; Frye D; Buzdar AU; Theriault RL; Valero V; Booser DJ; Singletary SE; Strom EA; Gajewski JL; Champlin RE; Hortobagyi GN
Cancer; 2006 Jun; 106(11):2327-36. PubMed ID: 16639731
[TBL] [Abstract][Full Text] [Related]
13. [High dosage therapy and autologous peripheral stem cell transplantation in breast carcinoma].
Kier P; Ruckser R; Buxhofer V; Habertheuer KH; Zelenka P; Tatzreiter G; Hübl G; Kittl E; Hauser A; Sebesta C; Hinterberger W
Acta Med Austriaca Suppl; 2000; 52():33-6. PubMed ID: 11261276
[TBL] [Abstract][Full Text] [Related]
14. High-dose chemotherapy and autologous stem cell support followed by posttransplantation doxorubicin as initial therapy for metastatic breast cancer.
deMagalhaes-Silverman M; Bloom E; Lembersky B; Lister J; Pincus S; Rybka W; Voloshin M; Wilson J; Ball E
Clin Cancer Res; 1997 Feb; 3(2):193-7. PubMed ID: 9815672
[TBL] [Abstract][Full Text] [Related]
15. [High-dosage chemotherapy and the autologous transplantation of peripheral hematopoietic progenitor cells in breast cancer: the initial results, analysis of toxicity and the necessary support means].
Sola Rocabert C; Mesía R; Mendoza L; Tabernero JM; Amill B; Maroto P; Bellet M; Ojeda B; Alonso MC; Verger G
Med Clin (Barc); 1995 Oct; 105(11):407-11. PubMed ID: 7475451
[TBL] [Abstract][Full Text] [Related]
16. A novel high-dose chemotherapy protocol with autologous hematopoietic rescue in patients with metastatic breast cancer or recurrent non-Hodgkin's lymphoma.
Fontelonga A; Kelly AJ; MacKintosh FR; Hall S; Monroe P; Wilson GS; Shaft D; Ruthven A; Ascensao JL
Bone Marrow Transplant; 1997 May; 19(10):983-8. PubMed ID: 9169642
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and toxicity of sequential high-dose therapy with peripheral blood stem cell support in patients with high-risk breast cancer.
Hohaus S; Wallwiener D; Martin S; Voso MT; Huober J; Fersis N; Bastert G; Haas R
Semin Oncol; 1998 Apr; 25(2 Suppl 4):7-11; discussion 45-8. PubMed ID: 9578056
[TBL] [Abstract][Full Text] [Related]
18. High-dose chemotherapy and autologous stem cell support followed by post-transplant doxorubicin and taxol as initial therapy for metastatic breast cancer: hematopoietic tolerance and efficacy.
deMagalhaes-Silverman M; Hammert L; Lembersky B; Lister J; Rybka W; Ball E
Bone Marrow Transplant; 1998 Jun; 21(12):1207-11. PubMed ID: 9674853
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of high-dose cyclophosphamide, etoposide, and carboplatin (CEC) followed by autologous hematopoietic stem cell rescue in women with metastatic or high-risk non-metastatic breast cancer: multivariate analysis of factors affecting survival and engraftment.
Klumpp TR; Goldberg SL; Magdalinski AJ; Mangan KF
Bone Marrow Transplant; 1997 Aug; 20(4):273-81. PubMed ID: 9285541
[TBL] [Abstract][Full Text] [Related]
20. [High-dose chemotherapy with four drugs and peripheral blood progenitor cell autologous transplantation in disseminated breast cancer].
Martín M; Casado A; Llorente L; López Martín JA; Rodríguez Lescure A; Nieto Y; Ayala F; Pérez Calvo J; Alonso JL; Pérez López C; Villegas A; Díaz-Rubio E
Med Clin (Barc); 1997 Dec; 109(20):775-81. PubMed ID: 9493155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
